A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis

Recently, more emphasis has been placed on patient-reported outcomes in clinical trials, which has inadvertently led to an increase in respondent burden. In this study, we found that the Skindex-16 form captures patient-reported quality of life in dermatomyositis as well as the Skindex-29 form but with fewer questions. Additional questions regarding photosensitivity, body image and cosmetic use did not correlate with skin activity in dermatomyositis.